How does hexarelin compare to GHRP-2 and GHRP-6 for GH release?

Hexarelin produces the highest acute GH peaks of any synthetic GHRP — higher than GHRP-2, GHRP-6, or ipamorelin at equivalent doses, confirmed in human studies (Laron et al., JCEM 1995). This is attributed to its exceptionally high GHS-R1a affinity and modified amino acids (D-2-methyl-Trp at position 2, D-Phe at position 5) that enhance receptor binding and protease resistance. The trade-off: similar cortisol/prolactin elevation to GHRP-2, and moderate hunger stimulation (between ipamorelin's minimal and GHRP-6's intense appetite effects). Unique to hexarelin: the additional CD36/GHS-R1b cardiac mechanism that no other GHRP has.

What is hexarelin's cardiac protection mechanism?

Hexarelin activates CD36 (a scavenger receptor in cardiomyocytes) and GHS-R1b (a truncated ghrelin receptor isoform in cardiac tissue) through a mechanism completely independent of GH release. This CD36/GHS-R1b activation drives ERK1/2 and Akt survival signaling in cardiomyocytes, upregulates anti-apoptotic Bcl-2, and reduces infarct size by 30–50% in rodent ischemia-reperfusion models. Crucially, the cardiac mechanism was confirmed in GH-deficient animals, establishing it is GH-independent. Ex vivo human cardiac tissue study (Siddiqui et al., Eur Heart J 2009) confirmed the mechanism operates in human cardiomyocytes.

What is tachyphylaxis with hexarelin and how do you manage it?

Daily hexarelin use can produce tachyphylaxis — reduced GH response over weeks as GHS-R1a receptors desensitize. This is less of an issue at 3x per week vs. daily dosing. Management: limit to 3x per week maximum; if the characteristic GH flush and tingling diminish over weeks, take 2 weeks off before restarting to restore receptor sensitivity. Rotating with other GHRPs (ipamorelin, GHRP-2) during breaks can maintain a GH protocol while allowing hexarelin's receptor sensitivity to recover.

When should I choose hexarelin vs. GHRP-2 vs. ipamorelin?

Hexarelin: maximum GH release + unique GH-independent cardiac protection (CD36/GHS-R1b). Choose for post-MI recovery, cardiac optimization alongside GH, or when maximum GH is the priority. GHRP-2: maximum GH release without the cardiac mechanism; slightly less potent than hexarelin but the classic high-GH stack with CJC-1295. Ipamorelin: clean, selective GH with minimal cortisol, prolactin, or appetite — best for long-term conservative GH optimization. GHRP-6: maximum GH + intentional appetite stimulation for mass-building phases.

COMPOUND LIBRARY·HEXARELIN

COMPOUND PROFILE · PEPPERLEDGER

Hexarelin (Examorelin)

Type

Synthetic hexapeptide — His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂ — ghrelin receptor agonist and CD36/GHS-R1b ligand

Class

GH secretagogue (most potent GHRP) · Cardioprotective peptide via CD36/GHS-R1b mechanism independent of GH

Administration

Subcutaneous injection · Intranasal (investigated) · IV (research)

Half-life

~30–60 minutes

Most studied use

Maximum GH release · Cardiac protection · Recovery · Body composition

Regulatory status

Not FDA-approved · Category 1 compound · Research chemical · Under investigation for cardiac protection

Human evidence

Good — multiple human PK/PD studies confirming GH potency; ex vivo human cardiac tissue CD36 activation confirmed; cardiac protection preclinical independently replicated

Preclinical evidence

Exceptional — most studied GHRP for cardiac protection; 30+ years of research

EDUCATIONAL TOOL — NOT MEDICAL ADVICE

What is hexarelin?

Hexarelin occupies a unique position in the GH secretagogue space: it's simultaneously the most potent GH-releasing peptide in its class and the only GHRP with a well-characterized, GH-independent cardioprotective mechanism. Understanding both aspects is essential to understanding why hexarelin is more than just 'a stronger GHRP-6.'

On GH potency: hexarelin produces the highest acute GH peaks of any synthetic GHRP — higher than GHRP-2, GHRP-6, or ipamorelin at equivalent doses. This is attributed to its particularly high affinity for GHS-R1a (the ghrelin receptor) and its additional activity at hypothalamic receptors that suppress somatostatin. The trade-off is the same as with the other potent GHRPs: meaningful cortisol and prolactin elevation alongside GH. What differentiates hexarelin from GHRP-6 is that the appetite stimulation, while present, is somewhat less pronounced — hexarelin's hunger profile sits between ipamorelin's minimal hunger and GHRP-6's intense hunger.

On cardiac protection: hexarelin was discovered to activate CD36 (a scavenger receptor expressed in heart muscle) and GHS-R1b (a truncated ghrelin receptor isoform in cardiac tissue) through mechanisms completely independent of GH release. In multiple cardiac ischemia-reperfusion models, hexarelin reduced infarct size by 30–50% and preserved cardiac function. This cardiac mechanism was observed even in GH-deficient animals — confirming it's GH-independent. Hexarelin is the only GHRP that has been specifically studied for this cardiac application.

How it works

GHS-R1a Agonism — Maximum GH Release

Hexarelin binds GHS-R1a (ghrelin receptor) with exceptionally high affinity, producing the strongest acute GH release of the GHRP family. Like GHRP-2 and GHRP-6, it also acts at the hypothalamic level to stimulate GHRH release and suppress somatostatin — triple amplification of GH secretion. The modified tryptophan at position 2 (D-2-methyl-Trp) and the D-phenylalanine at position 5 contribute to both receptor affinity and protease resistance compared to earlier GHRPs.

CD36 and GHS-R1b — Cardiac Protection Independent of GH

Hexarelin's cardiac mechanism operates through CD36 (a multifunctional scavenger receptor in cardiomyocytes) and GHS-R1b (the truncated, non-signaling ghrelin receptor isoform that forms heterodimers with CD36 in cardiac tissue). Hexarelin binding to this CD36/GHS-R1b complex activates ERK1/2 and Akt survival signaling, upregulates anti-apoptotic Bcl-2, and reduces pro-apoptotic Bax — providing direct protection against ischemia-reperfusion injury. This mechanism is completely independent of GH release, confirmed in GH-deficient animals.

Cortisol, Prolactin, and Tachyphylaxis

Like GHRP-2 and GHRP-6, hexarelin produces cortisol and prolactin elevation through broad ghrelin receptor activation — similar in magnitude to GHRP-2. Daily use can produce tachyphylaxis (reduced GH response over time as GHS-R1a receptors desensitize) — less of an issue at 3x per week vs. daily dosing. Cycling and frequency management are important for maintaining GH response over longer protocols.

What the research shows

HUMAN EVIDENCE

STUDYEuropean Journal of Clinical Pharmacology · 1994

Growth hormone-releasing activity of hexarelin in humans — a dose-response study

Imbimbo BP, Mant T, Edwards M et al.

Double-blind human dose-response study: intravenous hexarelin (0.5–2 µg/kg) produced dose-dependent GH release in male volunteers, with the response near-maximal by 2 µg/kg (ED50 ≈ 0.5–0.6 µg/kg). Early clinical evidence establishing hexarelin as a potent, well-characterized GH secretagogue.

View on PubMed →

STUDYCirculation Research · 2002

CD36 mediates the cardiovascular action of GHRPs, including hexarelin

Bodart V et al.

Isolated rat hearts and CD36-deficient mice. Hexarelin's coronary vascular action required CD36 — it disappeared when CD36 was genetically absent. Identified CD36 (distinct from the GH-secretagogue receptor) as the mediator of GHRPs' direct cardiac effects — the basis for hexarelin's GH-independent cardioprotection.

View on PubMed →

KEY PRECLINICAL — CARDIAC PROTECTION

STUDYEndocrinology · 1999

Growth hormone-independent cardioprotective effects of hexarelin in the rat

Locatelli V et al.

Rat ischemia-reperfusion (isolated heart) model. Hexarelin preserved contractility, blunted the rise in left-ventricular end-diastolic and coronary perfusion pressures, sustained protective prostacyclin release, and lowered creatine-kinase leakage — protecting the heart even after hypophysectomy, confirming the effect is growth-hormone-independent and acts through cardiac receptors.

View on PubMed →

WHAT THE RESEARCH SHOWS

✓KNOWN

✓Most potent GH-releasing GHRP in humans — confirmed in PK/PD studies (Laron 1995)
✓CD36/GHS-R1b cardiac mechanism confirmed in ex vivo human cardiac tissue
✓Infarct size reduction 30–50% in multiple rodent models — independently replicated
✓GH-independent cardiac mechanism — confirmed in GH-deficient animals
✓Cortisol and prolactin elevation alongside GH — same as GHRP class

?UNCERTAIN

?Whether cardiac protection translates to meaningful human clinical outcomes (no RCT)
?Optimal dose for cardiac protection vs. GH release (different goals may require different doses)
?Long-term safety beyond research use durations
?Head-to-head vs. GHRP-2 for GH release and cardiac outcomes

What the community reports

—Strongest GH spikes of any injectable GHRP — consistently reported as exceeding GHRP-2 and GHRP-6 at comparable doses

—Significant GH flush and tingling — a distinct sensation of GH elevation noticed within 15–30 minutes of injection; useful early indicator of tachyphylaxis if diminishing

—Appetite increase present but moderate — less intense than GHRP-6; more than ipamorelin

—Cardiac protection framing: subset of users specifically choose hexarelin for its cardiac mechanism — post-MI recovery, cardiac optimization alongside GH benefits

—Tachyphylaxis: reduced GH response noted in some long-term daily users; 3x/week protocols avoid this more consistently than daily dosing

Common misconceptions

"Hexarelin is just a more potent GHRP-6."

REALITY

Hexarelin and GHRP-6 both activate GHS-R1a but hexarelin has additional CD36/GHS-R1b cardiac receptor activity that GHRP-6 does not. The cardiac protection mechanism is unique to hexarelin in the GHRP family and operates completely independently of GH release. More potent GH release + unique cardiac mechanism makes hexarelin mechanistically distinct, not just stronger.

"Hexarelin's cardiac effects are proven in humans."

REALITY

The CD36/GHS-R1b cardiac mechanism has been confirmed in ex vivo human cardiac tissue. The infarct reduction and functional preservation data is from rodent models. A human cardiac protection RCT has not been conducted. The mechanism operates in human cardiac tissue; whether it produces clinically meaningful cardiac protection in humans requires clinical trials.

"You can use hexarelin daily without concern."

REALITY

Daily hexarelin use can produce tachyphylaxis — reduced GH response over time as GHS-R1a desensitizes. Pulsatile, less frequent use (3x/week maximum) preserves receptor sensitivity. If the GH flush diminishes over weeks, take 2 weeks off before restarting.

GHRP FAMILY DECISION FRAMEWORK

Hexarelin: maximum GH + unique GH-independent cardiac protection (CD36/GHS-R1b). GHRP-2: maximum GH, no cardiac mechanism, classic CJC stack. Ipamorelin: clean selective GH with minimal cortisol or appetite. GHRP-6: maximum GH + intentional appetite for mass-building.

RECONSTITUTION CALCULATOR

Peptide in vial (mg)BAC water (mL)Desired dose (mcg)

EDUCATIONAL TOOL — NOT MEDICAL ADVICE · VERIFY WITH YOUR CLINICIAN

AI RESEARCHER PREVIEW

I want maximum GH from a GHRP. Should I use Hexarelin or GHRP-2 + CJC-1295?

This is the right comparison to make, and the answer depends on whether the cardiac mechanism matters for you. Let me break both options down so you can make a protocol decision. Hexarelin solo or with CJC-1295: hexarelin produces the highest acute GH peaks of any synthetic GHRP — confirmed in human studies. The GH flush is real and typically noticeable within 15–30 minutes of injection. Hexarelin also activates CD36/GHS-R1b in cardiac tissue independently of GH — this is the unique mechanism no other GHRP has. In rodent ischemia models it reduced infarct size 30–50%; confirmed in ex vivo human cardiac tissue. Whether this produces meaningful cardiac protection in living humans hasn't been tested in an RCT. GHRP-2 + CJC-1295 (no-DAC): GHRP-2 produces slightly lower GH peaks than hexarelin but is well-established with decades of community data. The CJC-1295 component adds GHRH receptor stimulation, creating dual-receptor synergistic GH elevation — the combination produces meaningfully more GH than either alone. The CJC component is something hexarelin alone doesn't include, so hexarelin + CJC-1295 is actually the more apt comparison — and that combination rivals GHRP-2 + CJC in GH output. Tachyphylaxis consideration: hexarelin develops tolerance faster with daily use than GHRP-2 does. For either, 3x per week maximum preserves receptor sensitivity. If you're specifically interested in the cardiac protection aspect — post-cardiovascular event recovery, cardiac optimization, or running a GH protocol alongside existing heart concerns — hexarelin is the choice because it's the only GHRP with that mechanism. If you want maximum GH from a well-established protocol without the cardiac consideration, GHRP-2 + CJC-1295 has more community protocol data. Cortisol profile: both hexarelin and GHRP-2 produce similar cortisol elevation. The hunger effect with hexarelin is moderate — between ipamorelin's minimal and GHRP-6's intense. What's the primary goal — GH optimization for body composition, sleep/recovery, or specifically the cardiac mechanism?

CONTINUE IN THE APP

Open PepperLedger to build your Hexarelin protocol →

Free to join. No credit card. Ask the Researcher about your GH secretagogue stack once you're in.

Free to join · No credit card · 23-day Pro trial included